RIGL Rigel Pharmaceuticals Inc. (New)
XNAS
49.91
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
RIGL
$49.91
—
Key stats
$49.91
- 52-Week Range
- $24.95 – $52.24
- YTD
- +19.32%
- IV Rank (30D)
- 75.39
- Straddle Price
- $8.57
- P/C Vol Ratio
- 1.44
- Market Cap
- $0.9B
- Open
- $48.63
- Day Range
- $48.32 – $50.00
- Volume
- 196,564
- Prev Close
- $48.13
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.96% |
| Beta vs SPY | 0.98 |
| Cost of Equity (CAPM) | 9.87% (VRP-adj) |
| WACC | 10.02% |
| Volatility Risk Premium | +50.5pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +13.3% |
| DCF Horizon | 12 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $0.1B |
| Return on Equity (TTM) | 75.7% |
| Book / Price | 44.1% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 91.4% |
| FCF Margin (TTM) | 28.7% |
| Debt / Equity | 0.00 |
| Quality Score | 5/6 — high quality (12y DCF) |
| Market-Implied Growth | -0.4% (reverse-DCF on current price) |
| SMA 50 | $47.18 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $47.87 |
| Bollinger Width / SMA20 | 18.3% (drives anchor stability) |
| Net Debt | $-0.1B |
| Market Cap | $1B |
Peers used for multiples: ABT, NVS, PFE
(SIC-code peers; ETF co-membership was sector-incoherent)
Blended Fair Value
$140.91
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $113.10 | 23% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | $733.62 | 10% | median 39.5× · 3 peers |
| Peer EV/EBITDA | $101.14 | 10% | median 19.2× · 3 peers |
| Peer P/B | $77.32 | 2% | median 3.5× · 3 peers |
| Peer P/S | $60.69 | 7% | median 3.9× · 3 peers |
| Market Anchor (SMA50) | $47.18 | 27% | stability 59% (BB-width) |
| Options Expected (B-L 30d) | $50.80 | 21% | 18 strikes · skew +0.14 |
As of 2026-10-27 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.9B
- Employees
- 174
- List Date
- 2000-11-29
- CIK
- 0001034842
- Next Earnings
- 2026-11-03 (Pre-Market)
- EPS Forecast
- $0.87 (2 est.)
- Headquarters
- South San Francisco, CA
- Homepage
- https://www.rigel.com
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 4.90% | -6.57% | 22.39% | -19.86% | 25.00% | -16.66% | 1.53% |
| Feb | 9.79% | -3.09% | -12.21% | 26.67% | 8.98% | -3.53% | 4.43% |
| Mar | -23.49% | 19.12% | -15.38% | -4.52% | -19.58% | -21.89% | -10.96% |
| Apr | 8.45% | -26.02% | -11.02% | -21.64% | 14.05% | 5.09% | -5.18% |
| May | 1.92% | -26.42% | 17.65% | -10.29% | 2.56% | 3.71% | -1.81% |
| Jun | 18.58% | -35.06% | -7.86% | -16.39% | -7.05% | 31.01% | -2.80% |
| Jul | -11.11% | -4.80% | 5.34% | 25.80% | 12.56% | -4.79% | 3.83% |
| Aug | -5.47% | 17.36% | -14.29% | 34.00% | 77.32% | 23.38% | 22.05% |
| Sep | -11.68% | -23.38% | -8.47% | 23.32% | -26.34% | 1.37% | -7.53% |
| Oct | -4.82% | -38.25% | -21.62% | -16.74% | 12.14% | 6.26%* | -10.51% |
| Nov | -24.58% | -10.83% | 42.98% | 94.44% | 64.73% | -- | 33.35% |
| Dec | 1.92% | 119.27% | 33.03% | -37.82% | -9.37% | -- | 21.41% |
| Total | -37.29% | -60.59% | 8.05% | 19.21% | 193.17% | 13.46% | 22.67% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $47.87
SMA 50: $47.18
SMA 200: $36.92
Current: $49.91
EMA 12: $48.19
EMA 26: $47.66
MACD: 0.5259 | Signal: 0.0962
BULLISH
ADX (14): 12.81
RANGE
+DI: 27.86
−DI: 21.33
Momentum Oscillators
RSI (14): 60.13
NEUTRAL
Stoch %K: 71.11
Stoch %D: 66.72
Williams %R: -10.99
Volume & Volatility
BB Upper: $49.96
BB Lower: $45.78
NEUTRAL
OBV: 3,876,829
Vol SMA 20: 214,676
Vol ROC: 20.77%
ATR: $1.72
True Range: $1.87
HV 20: 35.2%
HV 30: 33.6%
HV 60: 38.9%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report - RIGL
Executive Summary
BULLISH (Confidence Level: 8/10)
Key drivers: Positive recent news headlines, increasing trend strength, and low volatility.
Primary risks: Regulatory uncertainty, market sentiment shifts.
2-3 sentence investment thesis: RIGL is a solid long-term bet, with a strong pipeline of innovative cancer treatments driving growth. The stock's low volatility and positive earnings momentum create an attractive risk-reward profile.
Recent news sentiment impact: Positive recent news headlines have had a significant impact on the stock's price movement, particularly the partnership announcements with Arvinas and Pfizer.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): Uptrend
- Medium-term (1-3 months): Uptrend
- Long-term (3-12 months): Uptrend
Support/Resistance Levels:
- Upper: $46.00
- Middle: $40.49
- Lower: $34.98
Momentum Signals:
- RSI interpretation: 65.15 (neutral)
- MACD signal: Bullish (1.73 / Signal: 0.54 / Histogram: 1.19)
- Bollinger Bands position: Neutral (middle band = $40.49)
Volume Analysis:
- Volume SMA 20: 317035.33
- On-Balance Volume (OBV): 1224585.25
- Volume Rate of Change: -47.51% (indicating a decrease in volume)
News & Sentiment Analysis
Recent Headlines Summary:
- Onco360 selected as national pharmacy partner for VEPPANU.
- Rigel Inks breast cancer drug deal with Arvinas, Pfizer.
- Rigel Q2 revenue jumps 176%.
- Thérapeutique Knight announces regulatory approval of TAVALISSE in Mexico.
- T-Cell Lymphoma pipeline insight analysis report highlights regulatory support for novel drugs.
Sentiment Assessment: POSITIVE
Catalyst Identification:
- Regulatory approvals (e.g., VEPPANU, TAVALISSE)
- Earnings reports
- Product launches
- Analyst upgrades
Market Narrative: The recent news headlines have created a positive market narrative around RIGL's pipeline and regulatory progress. This sentiment aligns with the technical signals indicating an uptrend.
Risk & Volatility Assessment
Risk Assessment: LOW (Beta: 0.74, Alpha: 0.16, Correlation: 0.15)
Volatility Regime:
- Current volatility: Low (stock moves less than market)
- Historical volatility: Medium (HV20: 48.3%, HV30: 46.6%, HV60: 42.7%)
Options Market Signals:
- IV Rank: Low (0.0%)
- Current IV: 72.1%
- Expected Move: $4.80 (29 DTE), 7-DTE: $1.52
- Volume Flow: Neutral (103 calls vs 102 puts)
- Open Interest: Neutral (1,268 calls vs 389 puts)
Downside Protection:
- Support levels: Middle band ($40.49) and Lower band ($34.98)
Market Context & Positioning
Sector Performance:
- Relative strength: Cancer treatment sector performing well
Institutional Activity:
- Volume patterns suggesting institutional interest: Positive (103 calls vs 102 puts)
Correlation Analysis:
- R-squared interpretation: Low correlation with market, indicating a unique risk profile
Relative Valuation:
- Position within trading range: Strongly above middle band ($40.49), indicating room for further growth
Key Levels & Action Items
Critical Price Levels:
- Support: Middle band ($40.49) and Lower band ($34.98)
- Resistance: Upper band ($46.00)
Breakout/Breakdown Levels:
- Technical levels that could trigger significant moves: Above $46.00 or below $34.98
Time-Sensitive Catalysts:
- Regulatory approvals (e.g., VEPPANU, TAVALISSE)
- Earnings reports
- Product launches
Risk Management:
- Stop-loss levels: Below the Lower band ($34.98) and above the Upper band ($46.00)
- Position sizing considerations: Consider reducing positions if IV rank increases or volume flow shifts bearishly
Generated
News
All RIGL news →
Earnings History
20 of 26 under expected move
Avg Expected Move
13.63%
Avg Actual Move
4.52%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-01-11 | Pre-Market | 1.56% | 4.47% | 2.87x | Exceeded |
| 2021-03-02 | Pre-Market | 24.94% | 3.69% | 0.15x | Within |
| 2021-05-05 | Pre-Market | 16.19% | 0.87% | 0.05x | Within |
| 2021-08-03 | Pre-Market | 0.87% | 5.97% | 6.86x | Exceeded |
| 2021-11-02 | Pre-Market | 0.56% | 0.85% | 1.52x | Exceeded |
| 2022-01-10 | Pre-Market | 2.54% | 0.79% | 0.31x | Within |
| 2022-08-02 | Pre-Market | 0.58% | 7.44% | 12.83x | Exceeded |
| 2023-01-09 | Pre-Market | 3.36% | 12.80% | 3.81x | Exceeded |
| 2023-03-07 | Pre-Market | 12.43% | 3.29% | 0.26x | Within |
| 2023-05-02 | Pre-Market | 0.84% | 4.20% | 5.00x | Exceeded |
| 2023-08-01 | Pre-Market | 7.46% | 3.62% | 0.49x | Within |
| 2023-11-07 | Pre-Market | 30.12% | 3.51% | 0.12x | Within |
| 2024-01-08 | Pre-Market | 30.37% | 7.25% | 0.24x | Within |
| 2024-03-05 | Pre-Market | 17.24% | 0.68% | 0.04x | Within |
| 2024-05-07 | Pre-Market | 15.00% | 2.46% | 0.16x | Within |
| 2024-08-06 | Pre-Market | 29.83% | 6.02% | 0.20x | Within |
| 2024-11-07 | Pre-Market | 12.77% | 2.39% | 0.19x | Within |
| 2025-01-13 | Pre-Market | 21.23% | 5.29% | 0.25x | Within |
| 2025-03-04 | Pre-Market | 16.76% | 1.30% | 0.08x | Within |
| 2025-05-06 | Pre-Market | 10.20% | 4.45% | 0.44x | Within |
| 2025-08-05 | Pre-Market | 17.09% | 6.93% | 0.41x | Within |
| 2025-11-04 | Pre-Market | 17.46% | 7.41% | 0.42x | Within |
| 2026-01-12 | Pre-Market | 12.18% | 2.15% | 0.18x | Within |
| 2026-03-03 | After-Close | 23.02% | 10.27% | 0.45x | Within |
| 2026-05-05 | Pre-Market | 14.05% | 4.91% | 0.35x | Within |
| 2026-08-04 | After-Close | 15.83% | 4.60% | 0.29x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
RIGL Options Activity & IV Rank
RIGL IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 76.4%
7-DTE IV: —
Expected Move: $8.57
7-DTE Move: $8.57
Days to Exp: 25 (2026-11-20)
Options Flow
Call Volume: 36
Put Volume: 52
P/C Volume: 1.444
BEARISH
Call OI: 297
Put OI: 71
P/C OI: 0.239
Total OI: 368
ATM Options Pricing
ATM Call: $4.17
ATM Put: $4.40
Call %: 8.4%
Put %: 8.8%
Chain Summary
Chain Volume: 474
Chain OI: 1,561
Last Updated: 10/26/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
HIGH γ vs HISTORY
Estimated net dealer gamma is at the 87th percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
87%
vs own history
GEX tilt
+0.85
OI-weighted, today
Vanna tilt
+0.39
δ-sensitivity to IV
Charm tilt
-0.45
δ-decay vs time
Vanna tilt +0.39: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.45: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 11 ATM contracts, 0k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · ATM 82.6% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)75.4HighOct 26
Straddle Price (30 DTE)$8.57Oct 26
Beta Analysis
Risk Metrics
Beta: 0.8187
Alpha: 59.34%
Correlation: 0.1656
R-Squared: 2.7%
Stock Volatility: 63.0%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Moderate volatility - stock generally follows market
Moderate volatility - stock generally follows market
Beta & Alpha Over Time
Notable investors who own RIGL
3 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $5.7M | #1385 of 3138 | -56.9% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $3.7M | #2246 of 3716 | -64.6% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $4K | #4285 of 4729 | 0.0% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
RIGL Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 19,313,000 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
6 filers$4.49M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $2.69M | 59.88% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $962.35K | 21.44% | 2026-06-30 |
| 3 | Wolverine Trading, LLC Custodian | $376.62K | 8.39% | 2025-09-30 |
| 4 | Jane Street Group, LLC Custodian | $285.58K | 6.36% | 2026-06-30 |
| 5 | Simplex Trading, LLC Custodian | $97.80K | 2.18% | 2026-06-30 |
| 6 | GROUP ONE TRADING LLC Custodian | $78.24K | 1.74% | 2026-06-30 |
3 filers$2.53M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $1.64M | 64.61% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $668.95K | 26.43% | 2026-06-30 |
| 3 | Simplex Trading, LLC Custodian | $226.90K | 8.96% | 2026-06-30 |
RIGL Insider Trading (Form 4)
Latest: 2026-09-03Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-03 | David A Santos | EVP, Chief Commercial Officer | Tax (F) | −874 | $47.50 | -$41.5K | EDGAR |
| 2026-09-03 | Raymond J. Furey | EVP, GC, CCO & Corp Sec | Tax (F) | −877 | $47.50 | -$41.7K | EDGAR |
| 2026-09-03 | Raul R Rodriguez | CEO, President | Tax (F) | −2,424 | $47.50 | -$115.1K | EDGAR |
| 2026-09-03 | Dean L Schorno | EVP & Chief Financial Officer | Mixed | +3,672 | $26.05 | $55.8K | EDGAR |
| 2026-07-10 | Alison L. Hannah | EVP, Chief Medical Officer | Award (A) | +24,400 | — | EDGAR | |
| 2026-06-24 | Kamil Ali-Jackson | Director | Sell (S) | −2,500 | $35.00 | -$87.5K | EDGAR |
| 2026-06-22 | David A Santos | EVP, Chief Commercial Officer | Grant (A) | +7,394 opt | — | EDGAR | |
| 2026-06-22 | Raymond J. Furey | EVP, GC, CCO & Corp Sec | Grant (A) | +7,394 opt | — | EDGAR | |
| 2026-06-22 | Raul R Rodriguez | CEO, President | Grant (A) | +31,700 opt | — | EDGAR | |
| 2026-06-22 | Dean L Schorno | EVP & Chief Financial Officer | Grant (A) | +7,394 opt | — | EDGAR | |
| 2026-06-22 | Lisa Rojkjaer | EVP, Chief Medical Officer | Grant (A) | +16,769 opt | — | EDGAR | |
| 2026-06-03 | Dean L Schorno | EVP & Chief Financial Officer | Mixed | +2,453 | $18.07 | $22.4K | EDGAR |
| 2026-06-03 | David A Santos | EVP, Chief Commercial Officer | Tax (F) | −874 | $29.86 | -$26.1K | EDGAR |
| 2026-06-03 | Raymond J. Furey | EVP, GC, CCO & Corp Sec | Tax (F) | −877 | $29.86 | -$26.2K | EDGAR |
| 2026-06-03 | Raul R Rodriguez | CEO, President | Tax (F) | −2,424 | $29.86 | -$72.4K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
RIGL Insider Holdings
12 insiders · @ $49.91
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Raul R Rodriguez | CEO, President | 273,362 | $13.64M | $692.6K | 46 | 2026-09-03 |
| 2 | Dean L Schorno | EVP & Chief Financial Officer | 78,362 | $3.91M | $2.6K | 30 | 2026-09-03 |
| 3 | David A Santos | EVP, Chief Commercial Officer | 61,622 | $3.08M | -$109.3K | 20 | 2026-09-03 |
| 4 | Raymond J. Furey | EVP, GC, CCO & Corp Sec | 50,559 | $2.52M | -$59.7K | 12 | 2026-09-03 |
| 5 | Alison L. Hannah | EVP, Chief Medical Officer | 35,025 | $1.75M | $0 | 8 | 2026-07-10 |
| 6 | Lisa Rojkjaer | EVP, Chief Medical Officer | 34,003 | $1.70M | $0 | 8 | 2026-06-22 |
| 7 | Walter H Moos | Director | 18,472 | $921.9K | -$145.4K | 21 | 2026-05-19 |
| 8 | Anthony Gregg Lapointe | Director | 18,250 | $910.9K | $0 | 10 | 2026-05-19 |
| 9 | Jane Wasman | Director | 18,250 | $910.9K | $0 | 9 | 2026-05-19 |
| 10 | Kamil Ali-Jackson | Director | 10,125 | $505.3K | -$160.4K | 8 | 2026-06-24 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
RIGL Board & Officers
As of SEC filings through Sep 3, 2026Directors 8
- Walter H Moos · on file since May 2006
- Raul R Rodriguez · listed since Jan 2015
- Anthony Gregg Lapointe · since Oct 31, 2017
- Jane Wasman · since Apr 1, 2019
- Alison L. Hannah · since May 14, 2021
- Kamil Ali-Jackson · since Dec 16, 2021
- Mark W Frohlich · since Mar 6, 2025
- Michael Patrick Miller · since Feb 1, 2026
Officers 5
- Raul R Rodriguez · CEO, President · listed since Jan 2015
- Dean L Schorno · EVP & Chief Financial Officer · since May 29, 2018
- David A Santos · EVP, Chief Commercial Officer · since Aug 10, 2020
- Alison L. Hannah · EVP, Chief Medical Officer · listed since Jul 2026
- Raymond J. Furey · EVP, GC, CCO & Corp Sec · listed since Jan 2024
Changes in the last 10 years (22)
| Jul 10, 2026 | Alison L. Hannah first listed as EVP, Chief Medical Officer in an SEC filing |
| Jun 25, 2026 | The company announced the departure of Lisa Rojkjaer as EVP, Chief Medical Officer in an SEC filing |
| Feb 1, 2026 | Michael Patrick Miller became a director |
| Mar 6, 2025 | Mark W Frohlich became a director |
| Sep 16, 2024 | The company announced the departure of Brian L. Kotzin from the board in an SEC filing |
| Mar 27, 2024 | Lisa Rojkjaer became EVP, Chief Medical Officer |
| Jan 25, 2024 | Raymond J. Furey listed as EVP, GC, CCO & Corp Sec (previously EVP, GC & Corp Sec) in SEC filings |
| Dec 9, 2022 | Raymond J. Furey became EVP, GC & Corp Sec |
| Dec 16, 2021 | Kamil Ali-Jackson became a director |
| May 14, 2021 | Alison L. Hannah became a director |
| Aug 10, 2020 | David A Santos became EVP, Chief Commercial Officer |
| Feb 7, 2020 | Nelson Cabatuan listed as VP,Finance & Princ.Acctg. Off. (previously Principal Accounting Officer) in SEC filings |
| Nov 20, 2019 | Wolfgang Dummer listed as EVP & CMO (previously Chief Medical Officer) in SEC filings |
| Nov 4, 2019 | Wolfgang Dummer became Chief Medical Officer |
| Apr 1, 2019 | Jane Wasman became a director |
| Jan 25, 2019 | Joseph Lasaga listed as Sr.VP Bus.Dev.Alliance Mgmt. (previously VP Bus. Dev.& Alliance Mgmt.) in SEC filings |
| May 29, 2018 | Dean L Schorno became EVP & Chief Financial Officer |
| Apr 24, 2018 | Anne-Marie Duliege listed as EVP & Chief Medical Officer (previously Chief Medical Officer) in SEC filings |
| Mar 19, 2018 | Stacy Markel became EVP Human Resources |
| Dec 18, 2017 | Nelson Cabatuan became Principal Accounting Officer |
| Oct 31, 2017 | Anthony Gregg Lapointe became a director |
| Aug 21, 2017 | Brian L. Kotzin became a director |
Not reported recently (13)
- Gary A Lyons · Last reported as a director in an SEC filing dated Jul 12, 2023
- Wolfgang Dummer · Last reported as EVP & CMO in an SEC filing dated Feb 6, 2023
- Dolly Vance · Last reported as EVP Corp. Affairs, G.C., Sect. in an SEC filing dated Sep 16, 2022
- Bradford S Goodwin · Last reported as a director in an SEC filing dated May 21, 2021
- Keith Katkin · Last reported as a director in an SEC filing dated May 21, 2021
- Nelson Cabatuan · Last reported as VP,Finance & Princ.Acctg. Off. in an SEC filing dated May 15, 2020
- Esteban Masuda · Last reported as Sr. VP Research in an SEC filing dated Nov 20, 2019
- Eldon C. Mayer III · Last reported as EVP & Chief Commercial Officer in an SEC filing dated Nov 20, 2019
- Joseph Lasaga · Last reported as Sr.VP Bus.Dev.Alliance Mgmt. in an SEC filing dated Nov 20, 2019
- Anne-Marie Duliege · Last reported as EVP & Chief Medical Officer in an SEC filing dated Mar 22, 2019
- Stacy Markel · Last reported as EVP Human Resources in an SEC filing dated Mar 22, 2019
- Peter S Ringrose · Last reported as a director in an SEC filing dated May 18, 2018
- Ryan D Maynard · Last reported as EVP & CFO in an SEC filing dated Nov 7, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
RIGL Proposed Insider Sales (Form 144)
Latest: 2026-06-22
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-06-22 | Ali-Jackson Kamil | Director | 2,500 | $87.5K | 2026-06-22 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-05-26 | Ali-Jackson Kamil | Director | 2,500 | $72.9K | 2026-05-26 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-02-20 | MOOS WALTER H | Director | 4,000 | $145.4K | 2026-02-20 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2025-02-05 | Santos David A | Officer | 1,796 | $39.4K | 2025-02-05 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2025-02-05 | Schorno Dean L | Officer | 1,734 | $38.0K | 2025-02-05 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2025-02-05 | Furey Raymond J. | Officer | 1,339 | $29.4K | 2025-02-05 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2025-02-05 | RODRIGUEZ RAUL R | Officer, Director | 4,400 | $96.5K | 2025-02-05 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2025-02-04 | Schorno Dean L | Officer | 2,036 | $42.6K | 2025-02-04 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2025-02-04 | RODRIGUEZ RAUL R | Officer, Director | 4,952 | $103.6K | 2025-02-04 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2025-02-04 | Furey Raymond J. | Officer | 1,448 | $30.3K | 2025-02-04 | Fidelity Brokerage Services LLC | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
62 ETFs hold RIGL
25 shown · $184.75M total exposure · 0.08% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | AVUV Avantis U.S. Small Cap Value ETF | Avantis | 0.14% | $44.8M | $32.2B | 2026-10-23 |
| 2 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $26.8M | — | 2026-09-30 |
| 3 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 0.23% | $24.2M | $10.4B | 2026-10-23 |
| 4 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.03% | $22.3M | $74.6B | 2026-10-23 |
| 5 | VXF Vanguard Extended Market ETF | Vanguard | 0.01% | $10.1M | — | 2026-09-30 |
| 6 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.06% | $8.2M | $13.9B | 2026-10-23 |
| 7 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.06% | $6.6M | $10.7B | 2026-10-23 |
| 8 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.03% | $5.2M | — | 2026-09-30 |
| 9 | FDM First Trust Dow Jones Select MicroCap Index Fund | First Trust | 1.46% | $3.9M | $268.3M | 2026-10-23 |
| 10 | CALF Pacer US Small Cap Cash Cows 100 ETF | Nport | 0.09% | $3.1M | — | 2026-07-31 |
| 11 | BSVO EA Bridgeway Omni Small-Cap Value ETF | Nport | 0.13% | $3.1M | — | 2026-06-30 |
| 12 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.01% | $2.7M | — | 2026-05-31 |
| 13 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.22% | $2.7M | $1.2B | 2026-10-23 |
| 14 | VHT Vanguard Health Care ETF | Vanguard | 0.01% | $2.6M | — | 2026-09-30 |
| 15 | IDNA iShares Genomics Immunology and Healthcare ETF | iShares (BlackRock) | 0.78% | $2.5M | $321.2M | 2026-10-23 |
| 16 | FDLS Inspire Fidelis Multi Factor ETF | Nport | 1.07% | $2.2M | — | 2026-05-31 |
| 17 | PSC Principal U.S. Small-Cap ETF | Nport | 0.09% | $2.0M | — | 2026-06-30 |
| 18 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.00% | $1.6M | — | 2026-10-23 |
| 19 | GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF | Goldman | 0.15% | $1.5M | $1.0B | 2026-10-23 |
| 20 | BBP Virtus Biotech Etf | Nport | 1.54% | $1.5M | — | 2026-07-31 |
| 21 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.02% | $1.5M | — | 2026-10-23 |
| 22 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.05% | $1.5M | $3.2B | 2026-10-23 |
| 23 | JPSE JPMorgan Diversified Return U.S. Small Cap Equity ETF | JPMorgan | 0.25% | $1.4M | $573.3M | 2026-10-26 |
| 24 | VFMF Vanguard U.S. Multifactor ETF | Vanguard | 0.12% | $1.4M | — | 2026-10-23 |
| 25 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.00% | $1.2M | — | 2026-10-23 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
2.96
TTM Diluted EPS
$16.88
TTM Revenue
$276.79M
TTM Net Income
$321.91M
TTM Op. Cash Flow
$79.39M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $78.70M | $17.29M | $0.88 | $30.65M |
| Q1 '26 | 2026-03-31 | $58.82M | $8.65M | $0.44 | $2.73M |
| Q4 '25 | 2025-12-31 | $69.80M | $268.06M | $14.10 | $21.98M |
| Q3 '25 | 2025-09-30 | $69.46M | $27.90M | $1.46 | $24.03M |
| Q2 '25 | 2025-06-30 | $101.69M | $59.61M | $3.28 | $30.54M |
| Q1 '25 | 2025-03-31 | $53.33M | $11.45M | $0.63 | $-893.00K |
| Q4 '24 | 2024-12-31 | $57.60M | $14.34M | $0.81 | $14.50M |
| Q3 '24 | 2024-09-30 | $55.31M | $12.42M | $0.70 | $21.68M |
| Q2 '24 | 2024-06-30 | $36.84M | $-1.03M | $-0.06 | $302.00K |
| Q1 '24 | 2024-03-31 | $29.53M | $-8.25M | $-0.47 | $-5.01M |
| Q4 '23 | 2023-12-31 | $35.79M | $737.00K | $0.05 | $-6.24M |
| Q3 '23 | 2023-09-30 | $28.13M | $-5.69M | $-0.33 | $-1.36M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-04
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
2.96
P/B
2.27
P/S
3.48
EV/EBITDA
10.07
EV/Sales
3.26
ROE
75.7%
ROA
61.8%
Div Yield
0.00%
FCF Yield
8.24%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$963.91M
as of 2026-10-26
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
2.86M
SI % of Float
17.07%
Days to Cover
11.14
Short Vol Ratio
60.1%
Free Float
16.73M
Float %
89.5%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-09-22